ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis

• Published in: PloS one Vol. 15; no. 2; p. e0229179
• Main Authors: Elliott, Jesse, Bai, Zemin, Hsieh, Shu-Ching, Kelly, Shannon E, Chen, Li, Skidmore, Becky, Yousef, Said, Zheng, Carine, Stewart, David J, Wells, George A
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 19.02.2020; Public Library of Science (PLoS)
• Subjects: Alectinib; Anaplastic Lymphoma Kinase - antagonists & inhibitors; Anopheles; Brigatinib; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - enzymology; Ceritinib; Chemotherapy; Clinical trials; Comparative analysis; Computer and Information Sciences; Crizotinib; Crossovers; Death; Drug therapy; Fatalities; Grey literature; Heart; Humans; Inhibitors; Kinases; Lorlatinib; Lung cancer; Lung diseases; Lung Neoplasms - drug therapy; Lung Neoplasms - enzymology; Lymphoma; Lymphomas; Medicine and Health Sciences; Meta-analysis; Methods; Mutation; Network Meta-Analysis; Non-small cell lung cancer; Non-small cell lung carcinoma; Operating systems (Software); Physical Sciences; Prejudice; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Protein-tyrosine kinase; Research and Analysis Methods; Research methodology; Risk analysis; Risk assessment; Small cell lung cancer; Small cell lung carcinoma; Survival; Systematic review; Tumors; Web portals; Canada; United States > US

We sought to assess the relative effects of individual anaplastic lymphoma kinase (ALK) inhibitors for the treatment of non-small cell lung cancer (NSCLC). We searched MEDLINE, Embase, Cochrane CENTRAL, and grey literature (July 23, 2019) for randomized controlled trials (RCTs) that included partici...